Discontinued — last reported Q2 '19
Available-for-Sale Debt Securities - Unrealized Loss Position
Current AssetsEli Lilly Available-for-Sale Debt Securities - Unrealized Loss Position decreased by 55.3% to $177.20M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 51.8%, from $367.60M to $177.20M. Over 4 years (FY 2020 to FY 2024), Available-for-Sale Debt Securities - Unrealized Loss Position shows an upward trend with a 156.2% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ3 2017
Last reportedQ2 2019
Metric ID:
afs_debt_securities_unrealized_loss_positionHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $164.80M | $208.10M | $290.20M | $440.60M | $489.20M | $578.80M | $568.70M | $512.40M | $570.60M | $559.60M | $452.00M | $477.90M | $508.40M | $367.60M | $491.20M | $435.90M | $396.80M | $177.20M |
| QoQ Change | — | +26.3% | +39.5% | +51.8% | +11.0% | +18.3% | -1.7% | -9.9% | +11.4% | -1.9% | -19.2% | +5.7% | +6.4% | -27.7% | +33.6% | -11.3% | -9.0% | -55.3% |
| YoY Change | — | — | — | — | +196.8% | +178.1% | +96.0% | +16.3% | +16.6% | -3.3% | -20.5% | -6.7% | -10.9% | -34.3% | +8.7% | -8.8% | -22.0% | -51.8% |
Range$164.80M – $578.80M
CAGR+1.7%
Avg YoY Growth+25.3%
Median YoY Growth-5.0%
Current Streak3 quarters decline
Available-for-Sale Debt Securities - Unrealized Loss Position at Other Companies
Frequently Asked Questions
- What is Eli Lilly's available-for-sale debt securities - unrealized loss position?
- Eli Lilly (LLY) reported available-for-sale debt securities - unrealized loss position of $177.20M in Q3 2025.
- How has Eli Lilly's available-for-sale debt securities - unrealized loss position changed year-over-year?
- Eli Lilly's available-for-sale debt securities - unrealized loss position decreased by 51.8% year-over-year, from $367.60M to $177.20M.
- What is the long-term trend for Eli Lilly's available-for-sale debt securities - unrealized loss position?
- Over 4 years (2020 to 2024), Eli Lilly's available-for-sale debt securities - unrealized loss position has grown at a 156.2% compound annual growth rate (CAGR), from $11.40M to $491.20M.